Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and sri 62-834

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with sri 62-834 in 3 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(sri 62-834)		Trials
(sri 62-834)		Recent Studies (post-2010) (sri 62-834)
9,1561875521600

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's2 (66.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dive, C; Watson, JV; Workman, P1
Donaldson, J; Lohmeyer, M; Workman, P1
Bazill, GW; Dexter, TM1

Other Studies

3 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and sri 62-834

ArticleYear
Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
    Cancer research, 1991, Feb-01, Volume: 51, Issue:3

    Topics: Animals; Antineoplastic Agents; Azepines; Cell Division; Cell Membrane Permeability; Flow Cytometry; Furans; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Mammary Neoplasms, Animal; Mice; Phospholipid Ethers; Platelet Activating Factor; Time Factors; Triazoles; Tumor Cells, Cultured

1991
Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
    Biochemical pharmacology, 1991, Jan-15, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Azepines; Calcium; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Furans; Humans; Leukemia, Promyelocytic, Acute; Phospholipid Ethers; Platelet Activating Factor; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured

1991
An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
    Biochemical pharmacology, 1989, Jan-15, Volume: 38, Issue:2

    Topics: Biological Transport; Cell Survival; Furans; Phospholipid Ethers; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Tumor Cells, Cultured

1989